Effect of glucosamine on apolipoprotein AI mRNA stabilization and expression in HepG2 cells

Metabolism: Clinical and Experimental

Volumn 53, Issue 6, 2004, Pages 766-771

  Haas, Michael J ^b   Wong, Norman C W ^b   Mooradian, Arshag D ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; CHLORAMPHENICOL ACETYLTRANSFERASE; GLUCOSAMINE; INSULIN; MESSENGER RNA; TRANSCRIPTION FACTOR SP1; TRYPAN BLUE;

ARTICLE; ASSAY; BINDING SITE; CELL LINE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HALF LIFE TIME; HUMAN; HUMAN CELL; LIVER CELL; MEASUREMENT; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN STABILITY; REPORTER GENE; TOXICITY; TURNOVER TIME;

APOLIPOPROTEIN A-I; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE; CELL NUCLEUS; CHLORAMPHENICOL O-ACETYLTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GLUCOSAMINE; GLUCOSE; HEPATOCYTES; HUMANS; NUCLEIC ACID HYBRIDIZATION; PROMOTER REGIONS (GENETICS); RNA STABILITY; RNA, MESSENGER;

EID: 3042854519     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2003.11.027     Document Type: Article

References (45)

1. Miller G.J., Miller N.E. Plasma-high-density lipoprotein concentration and development of ischaemic heart disease. Lancet. 1:1975;16-19
2. Karathanasis S.K. Lipoprotein metabolism High density lipoprotein. Monogr Hum Genet. 14:1992;140-171
3. Franceschini G., Merderna P., Sitori C.R. Reverse cholesterol transport Physiology and pharmacology. Atherosclerosis. 88:1991;99-107
4. Lopez-Candales A. Metabolic syndrome X A comprehensive review of the pathophysiology and recommended therapy. J Med. 32:2001;283-300
5. Vajo Z., Terry J.G., Brinton E.A. Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal women. Atherosclerosis. 160:2002;495-501
6. Duvillard L., Pont F., Florentin E., et al. Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis. 152:2000;229-237
7. Ginsberg H.N. Diabetic dyslipidemia Basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes. 45:(suppl 3):1996;S27-S30
8. Murao K., Wada Y., Nakamura T., et al. Effects of glucose and insulin on rat apolipoprotein A-I gene expression. J Biol Chem. 273:1998;18959-18965
9. Zheng X.L., Matsubara S., Diao C., et al. Activation of apolipoprotein AI gene expression by protein kinase A and kinase C through transcription factor, Sp1. J Biol Chem. 275:2000;31747-31754
10. Lam J.K., Matsubara S., Mihara K., et al. Insulin induction of apolipoprotein AI, role of Sp1. Biochem. 42:2003;2680-2690
11. McClain D.A. Hexosamines as mediators of nutrient sensing Relevance to obesity, insulin resistance, and diabetes. Curr Opin Endocrinol Diabetes. 8:2001;186-191
12. Sakai K., Clemmons D.R. Glucosamine induces resistance to insulin-like growth factor I (IGF-I) and insulin in Hep G2 cell cultures Biological significance of IGF-I/insulin hybrid receptors. Endocrinology. 144:2003;2388-2395
13. Cooksey R.C., Herbert L.F. Jr, Zhu J.-H., et al. Mechanism of hexosamine-induced insulin resistance in transgenic mice over expressing glutamine: fructose-6-phosphate amidotransferase: Decreased glucose transporter GLUT4 translocation and reversal by treatment with thiazolidinedione. Endocrinology. 140:1999;1151-1157
14. Roos M.D., Su K., Baker J.R., et al. O glycosylation of an Sp1-derived peptide blocks known Sp1 protein interactions. Mol Cell Biol. 17:1997;6472-6480
15. Han I., Kudlow J.E. Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol Cell Biol. 17:1997;2550-2558
16. Daniels M.C., Kansal P., Smith T.M., et al. Glucose regulation of transforming growth factor-α expression is mediated by products of the hexosamine biosynthesis pathway. Mol Endocrinol. 7:1993;1041-1048
17. Goldberg H.J., Scholey J.M., Fantus I.G. Glucosamine activates the plasminogen activator inhibitor 1 gene promoter through Sp1 DNA binding sites in glomerular mesangial cells. Diabetes. 49:2000;863-871
18. Marshall S., Bacote J., Traxinger R.R. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem. 266:1991;4706-4712
19. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248-254
20. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685
21. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Proc Natl Acad Sci USA. 76:1979;4350-4354
22. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 132:1987;6-13
23. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning. A Laboratory Manual. (ed 2) :1989;Cold Spring Harbor Press, Cold Spring Harbor, NY
24. Feinberg A.P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific-activity. Anal Biochem. 132:1983;6-13
25. 1 promoter. Biochemistry. 35:1996;8281-8288
26. Taylor A.H., Raymond J., Dionne J.M., et al. Glucocorticoid increases rat apolipoprotein A-I promoter activity. J Lipid Res. 37:1996;2232-2243
27. Murao K., Bassyouni H., Taylor A.H., et al. Hepatocyte nuclear factor 4 inhibits the activity of site A from the rat apolipoprotein AI gene. Biochemistry. 36:1997;301-306
28. Haas M.J., Pun K., Reinacher D., et al. Effects of ketoacidosis on rat apolipoprotein AI gene expression A link with acidosis but not with ketones. J Mol Endocrinol. 25:2000;129-139
29. Haas M.J., Reinacher D., Li J.-P., et al. Regulation of apoA1 gene expression with acidosis Requirement for a transcriptional repressor. J Mol Endocrinol. 27:2001;43-57
30. Gorman C.M., Moffat L.F., Howard B.H. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol. 2:1982;1044-1051
31. Herbomel P., Bourachot B., Yaniv M. Two distinct enhancers with different cell specificities coexist in the regulatory region of polyoma. Cell. 39:1984;653-662
32. Sariban E., Luebbers R., Kufe D. Transcriptional and posttranscriptional control of c-fos gene expression in human monocytes. Mol Cell Biol. 8:1988;340-346
33. Cosgrove D.E., Cox G.S. Enhancement by theophylline of the butyrate-mediated induction of choriogonadotropin α-subunit in HeLa cells. Arch Biochem Biophys. 280:1990;95-102
34. Kilbourne E.J., Widom R., Harnish D.C., et al. Involvement of early growth response factor EGR-1 in apolipoprotein A1 gene transcription. J Biol Chem. 270:1995;7004-7010
35. Karathanasis S.K. Apolipoprotein multigene family Tandem organization of human apolipoprotein AI, CIII, and AIV genes. Proc Natl Acad Sci USA. 82:1985;6374-6378
36. Walsh A., Azrolan N., Wang K., et al. Intestinal expression of the human apoA-I gene in transgenic mice is controlled by a DNA region 3′ to the gene in the promoter of the adjacent convergently transcribed apoC-III gene. J Lipid Res. 34:1993;617-623
37. Naganawa S., Ginsberg H.N., Glickman R.M., et al. Intestinal transcription and synthesis of apolipoprotein AI is regulated by five natural polymorphisms upstream of the apolipoprotein CIII gene. J Clin Invest. 99:1997;1958-1965
38. Georgopoulos S., Kan H.Y., Reardon-Alulis C., et al. The Sp1 sites of the human apoCIII enhancer are essential for the expression of the apoCIII gene and contribute to the hepatic and intestinal expression of the apoA-I gene in transgenic mice. Nucl Acids Res. 28:2000;4919-4929
39. Apostolopoulos J.J., Howlett G.J., Fidge N. Effects of dietary cholesterol and hypothyroidism on rat apolipoprotein mRNA metabolism. J Lipid Res. 28:1987;642-648
40. Staels B., Auwerx J., Chan L., van Tol A., et al. Influence of development, estrogens, and food intake on apolipoprotein A-I, A-II, and E mRNA in rat liver and intestine. J Lipid Res. 30:1989;1137-1146
41. Golder-Novoselsky E., Forte T.M., Nochols A.V., et al. Apolipoprotein A-I expression and high-density lipoprotein distribution in transgenic mice during development. J Biol Chem. 267:1992;20787-20790
42. Zolfaghari R., Ross C. Effect of vitamin A deficiency and retinoic acid repletion on intestinal and hepatic apolipoprotein A-I mRNA levels of adult rats. J Lipid Res. 35:1994;1985-1992
43. Tam S.-P., Deeley R.G. Regulation of apolipoprotein A-I gene expression by phenobarbital in the human hepatocarcinoma cell line, Hep3B. Atherosclerosis. 105:1994;235-243
44. Wu J.Y., Wu Y., Reaves S.K., et al. Apolipoprotein A-I gene expression is regulated by cellular zinc status in Hep G2 cells. Am J Physiol. 277:1999;C537-C544
45. 2 cells by TNFα and IL-1β Biochim Biophys Acta. 1623:2003;120-128